Description: The purpose of this session is to discuss hot topics pertaining to post-LDTI GAAP valuation for FIA and RILA products including FAS 133, market risk benefits, intangibles, and ceded GAAP. At the conclusion of this session, attendees will have a clear understanding of how the industry views GAAP approaches to indexed annuity products in a post-LDTI framework. In addition, attendees will learn about ongoing pain points in GAAP valuation for indexed annuities and areas of post-LDTI GAAP where the industry still has broad variation in methodology and application.

Description: Have you wondered: - As a U.S. insurer, should I try to understand the implication of International Financial Reporting Standard 17 (IFRS 17) on global insurers? - As a pricing actuary, do I need to learn about the financial evolution brought about by IFRS 17 and Long Duration Targeted Improvements (LDTI)? - As my organization's CFO, I have invested in the arduous implementation of the new standards. How do I get the best return on my investment?If the answer to any of the above is 'Yes,' then this session is for you!

Description: Long Duration Targeting Improvement's (LDTI's) roll-forward disclosure requirements include line items for the impact of actual variances from expected experience (A/E) for both net premiums and benefits. These aggregate A/E amounts provide some insight into how actual experience is emerging relative to expectations, but they do not provide insight into either the drivers of the deviations or their significance.

Description: Companies are looking to modernize their FP&A processes and functions to deliver actionable insights, particularly in light of regulatory changes such as IFRS 17, LDTI, and PBR. New key performance indicators (KPIs) are emerging and FP&A function needs to evolve and adapt to these new paradigms, being a key function in monitoring the company's financial performance. Discover perspectives from filers under different bases: statutory, GAAP and IFRS and come learn how to elevate and enrich data, models, processes, and technology amidst changes to regulatory reporting. You'll also cover key considerations for the optimal design and interaction model between Finance, Actuarial, and other departments.

Description: Almost half of recent FDA approvals have been for orphan drugs. This trend is expected to continue in 2023. Orphan drugs are priced more than 30 times higher than non-orphan drugs, therefore their cost burden in aggregate has the potential to overwhelm the budgets of payers, especially that of smaller health plans. Hear how the cost impact analysis for smaller health plans require different considerations than for a larger health plan when modeling the impact of rare diseases.

Description: The panel will discuss several product challenges including modeling hybrid/combo long-term care products, modeling benefit options that are difficult to model using deterministic methods, modeling current situs of care versus original situs of care, monitoring assumptions, streamlining experience studies within the Long-duration Targeted Improvements (LDTI) framework, and model decision making with limited credible data. The panel will then move into solutions observed to address some of the aforementioned challenges and the future of long-term care modelling

Description: This panel discussion will focus on how companies have been able to take advantage of the new US GAAP requirements, to develop and refine other performance indicators that provide additional insights into their business.

Description: With IFRS 17 effective this year, come learn about the performance management capabilities provided by IFRS 17 with traditional analysis under IFRS4, and with LDTI under USGAAP. You will begin with an introduction to the IFRS 17 landscape post implementation, followed by a comparison of profit measurement and earning analysis key performance indicators (KPIs) pre- and post-IFRS 17, and ends with an exploration of the common philosophy of earning recognition between LDTI and IFRS 17 beyond the calculation differences.

Description: Forward looking insurers are reimagining their businesses with key strategic aims around how they engage with their customers and how they make and implement decisions. Industry experts will present a maturity framework for assessing your progress with specific case studies for how to advance in the areas of Management Information, New Business, and Inforce Management.

Description: Statutory and GAAP metrics are useful for regulators, investors, and other external parties who require a consistent basis for viewing snapshots of companies at a point in time, however, their uses are more limited for managers who are tasked with making strategic decisions. Many insurers are turning to internally developed metrics such as value of new business (VNB) for better profitability insights at the point of sale and to understand how new business profitability changes over time. By leveraging existing models and reporting processes, insurers can reduce the additional effort involved, applying VNB toward applications such as pricing, capital allocation, and risk management. Discuss key considerations for developing and using VNB. Begin with a brief overview of VNB, including how VNB addresses specific shortcomings of Stat and GAAP. Next, discuss applications of VNB for life and annuity business and conclude with some implementation case studies.